Porcupine-IN-1

Cas No.:	2036044-77-4
SMILES:	FC1=C(C2=CC(C)=NC=C2)N=CC(CNC(C3=CC=C(C(C=CC=C4)=C4N5)C5=C3)=O)=C1
Formula:	C25H19FN4O
M.Wt:	410.44
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Porcupine-IN-1 is potent porcupine inhibitor with an IC50 of 0.5±0.2 nM.
Target:	IC50: 0.5±0.2 nM (Porcupine inhibitor)[1]
In Vivo:	Porcupine-IN-1 demonstrates moderate clearance under the treatment of human liver microsomes (57 mL/min/kg) and rat liver microsomes (24 mL/min/kg). It exhibits high clearance when treated with mouse microsomes (109 mL/min/kg)[1].
In Vitro:	Porcupine is an enzyme that catalyses the addition of palmitoleate to a serine residue in Wnt proteins, a process which is required for the secretion of Wnt proteins. Porcupine-IN-1 is as potent as the clinical compound LGK974 in a cell based STF reporter gene assay. Porcupine-IN-1 potently inhibits the secretion of Wnt3A, therefore is confirmed to be a porcupine inhibitor[1].
Cell Assay:	HEK293T cells are transfected with pLinbin-Wnt3A plasmid or vehicle control. The HEK293T cells are then treated with or without compounds (Porcupine-IN-1). Western Blot is used after 48 h to analyze both the cell lysis and culture medium[1].
References:	[1]. Xu Z, et al. Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.